Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome

Circulation: Cardiovascular Genetics

Volumn 8, Issue 2, 2015, Pages 383-388

  Franken, Romy ^a,e   Den Hartog, Alexander W ^a,e   Radonic, Teodora ^f   Micha, Dimitra ^g   Maugeri, Alessandra ^g   Van Dijk, Fleur S ^g   Meijers Heijboer, Hanne E ^g   Timmermans, Janneke ^h   Scholte, Arthur J ⁱ   Van Den Berg, Maarten P ^j   Groenink, Maarten ^a,b,e   Mulder, Barbara J M ^a,e   Zwinderman, Aeilko H ^c   De Waard, Vivian ^d   Pals, Gerard ^g  

^a Departments of Cardiology   (Netherlands)

^b Radboudumc   (Netherlands)

^c Clinical Epidemiology and Biostatistics ^*  (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^f Departments of Pathology   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

aneurysm; aortic root; FBN1 mutation; heterogeneity; Losartan; Marfan syndrome; MRI

Indexed keywords

COMPLEMENTARY DNA; FIBRILLIN 1; LOSARTAN; MESSENGER RNA; ACTIN BINDING PROTEIN; FIBRILLIN;

ADULT; AORTA ROOT; ARTICLE; BLOOD PRESSURE; COHORT ANALYSIS; CONTROLLED STUDY; DURAL ECTASIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HAPLOINSUFFICIENCY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARFAN SYNDROME; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PIGEON THORAX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; STATISTICAL SIGNIFICANCE; VASODILATATION; CLINICAL TRIAL; DOMINANT GENE; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; FEMALE; GENES, DOMINANT; HAPLOINSUFFICIENCY; HUMANS; LOSARTAN; MALE; MARFAN SYNDROME; MICROFILAMENT PROTEINS; MIDDLE AGED;

EID: 84929476677     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000950     Document Type: Article

References (23)

1. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-339. doi: 10.1038/352337a0.
2. Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34:3491-3500. doi: 10.1093/eurheartj/eht334.
3. http://omim.org/entry/154700
4. Mariucci EM, Lovato L, Rosati M, Palena LM, Bonvicini M, Fattori R. Dilation of peripheral vessels in Marfan syndrome: importance of thoracoabdominal MR angiography. Int J Cardiol. 2013;167:2928-2931. doi: 10.1016/j.ijcard.2012.08.001.
5. Franken R, Heesterbeek TJ, de Waard V, Zwinderman AH, Pals G, Mulder BJ, et al. Diagnosis and genetics of Marfan syndrome. Expert Opin Orphan Drugs. 2014;1-14.
6. Hollister DW, Godfrey M, Sakai LY, Pyeritz RE. Immunohistologic abnormalities of the microfibrillar-fiber system in the Marfan syndrome. N Engl J Med. 1990;323:152-159. doi: 10.1056/NEJM199007193230303.
7. Agg B, Benke K, Szilveszter B, Pólos M, Daróczi L, Odler B, et al. Possible extracardiac predictors of aortic dissection in Marfan syndrome. BMC Cardiovasc Disord. 2014;14:47. doi: 10.1186/1471-2261-14-47.
8. Franken R, den Hartog AW, de Waard V, Engele L, Radonic T, Lutter R, et al. Circulating transforming growth factor- as a prognostic biomarker in Marfan syndrome. Int J Cardiol. 2013;168:2441-2446. doi: 10.1016/j. ijcard.2013.03.033.
9. Milewicz DM, Grossfield J, Cao SN, Kielty C, Covitz W, Jewett T. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. J Clin Invest. 1995;95:2373-2378. doi: 10.1172/JCI117930.
10. Dietz HC, McIntosh I, Sakai LY, Corson GM, Chalberg SC, Pyeritz RE, et al. Four novel FBN1 mutations: significance for mutant transcript level and EGF-like domain calcium binding in the pathogenesis of Marfan syndrome. Genomics. 1993;17:468-475. doi: 10.1006/geno.1993.1349.
11. Hilhorst-Hofstee Y, Hamel BC, Verheij JB, Rijlaarsdam ME, Mancini GM, Cobben JM, et al. The clinical spectrum of complete FBN1 allele deletions. Eur J Hum Genet. 2011;19:247-252. doi: 10.1038/ejhg.2010.174.
12. Schrijver I, Liu W, Brenn T, Furthmayr H, Francke U. Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet. 1999;65:1007-1020. doi: 10.1086/302582.
13. Schrijver I, Liu W, Odom R, Brenn T, Oefner P, Furthmayr H, et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am J Hum Genet. 2002;71:223-237. doi: 10.1086/341581.
14. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE. Revised diagnostic criteria for the Marfan syndrome. Am J Med. Genet. 1996;62:417-426. doi: 10.1002/(SICI)1096-8628(19960424)62:43.0.CO;2-R.
15. Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M; COMPARE study group. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials. 2010;11:3. doi: 10.1186/1745-6215-11-3.
16. Liu W, Schrijver I, Brenn T, Furthmayr H, Francke U. Multi-exon deletions of the FBN1 gene in Marfan syndrome. BMC Med Genet. 2001;2:11.
17. Chen X, Lu H, Rateri DL, Cassis LA, Daugherty A. Conundrum of angiotensin II and TGF-? interactions in aortic aneurysms. Curr Opin Pharmacol. 2013;13:180-185. doi: 10.1016/j.coph.2013.01.002.
18. Franken R, Radonic T, den Hartog AW, Groenink M, Pals G, van Eijk M, Lutter R, Mulder BJM, Zwinderman AH, de Waard V, COMPARE study group. The revised role of TGF-? in aortic aneurysms in Marfan syndrome. Neth Heart J. 2015;23:116-121. doi: 10.1007/s12471-014-0622-0.
19. Nishimoto M, Takai S, Fukumoto H, Tsunemi K, Yuda A, Sawada Y, et al. Increased local angiotensin II formation in aneurysmal aorta. Life Sci. 2002;71:2195-2205.
20. Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-Ortega M. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 2005;111:2509-2517. doi: 10.1161/01. CIR.0000165133.84978.E2.
21. Faury G. Function-structure relationship of elastic arteries in evolution: from microfibrils to elastin and elastic fibres. Pathol Biol (Paris). 2001;49:310-325.
22. Zablocki D, Sadoshima J. Solving the cardiac hypertrophy riddle: The angiotensin II-mechanical stress connection. Circ Res. 2013;113:1192-1195. doi: 10.1161/CIRCRESAHA.113.302501.
23. Franken R, Hibender S, den Hartog AW, Radonic T, de Vries CJ, Zwinderman AH, et al. No beneficial effect of general and specific antiinflammatory therapies on aortic dilatation in Marfan mice. PLoS One. 2014;9:e107221. doi: 10.1371/journal.pone.0107221.